GRACE :: Lung Cancer

chemo

Denise Brock

Lung Cancer Video Library – Is There An Optimal Chemo Regimen For Squamous Non-Small Cell Lung Cancer (NSCLC)

Share

 

GRACE Cancer Video Library - Lung

 

Dr. Jared Weiss

We are pleased to have Dr. Jared Weiss, Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, bring us further updates for our 2017 Lung Cancer Video Library.

In this latest video, Dr. Weiss discusses Is There An Optimal Chemo Regimen For Squamous Non-Small Cell Lung Cancer (NSCLC).


 

 

 

 

 

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.


 We would like to thank the following companies for their support of this program

 

                

 

 

                        

 

 
 

 

 


  


GRACE Video

Using Non/Off-Targeted Therapies in Targeted Lung Cancer Populations

Share

Acquired Resistance Forum Video #6: Dr. Nate Pennell of the Cleveland Clinic discussed the other options available to patients with ALK, ROS1 and EGFR lung cancer, such as chemotherapy, Avastin, and immunotherapy.


GRACE Video

LDE225 and Small Cell Lung Cancer

Share

Dr. Cathy Pietanza of Memorial Sloan Kettering talks about a drug currently in clinical trials that may successfully treat small cell lung cancer. February 2014.


Dr West

Video Presentation on Second Line Chemo for Advanced NSCLC

Share

One of the core issues in managing advanced NSCLC is second line chemotherapy, which was established as improving survival several years ago. This video presentation provides a brief summary of the work that led to the common use of chemotherapy in previously treated patients. Most typically, this is taxotere (docetaxel) or alimta (pemetrexed), and this presentation describes why we focus most commonly on these chemo agents.

Importantly, another second line treatment option is the oral EGFR inhibitor tarceva (erlotinib), a targeted therapy and not standard chemotherapy. The work leading to the approval of tarceva as a second or third line treatment for advanced NSCLC will be covered in a separate presentation.

As with other presentations, below you’ll find links to the figures as well as the transcript for this program.

Second Line Chemo for Adv NSCLC Figures

Second Line Chemo for Adv NSCLC Transcript

Although the fact that this program is sponsored by Mr. Alec Brindle is mentioned in the program itself, I wanted give special thanks to Mr. Brindle for his support, financial and personal, in bringing OncTalk and then GRACE from an idea to a real mechanism for helping the cancer community.

We truly need additional support to continue these activities. I and the other people working to deliver great content here are extremely gratified by the kind comments of appreciation that people provide, but we can’t pay the people working on these programs with that. Please make a donation to help support these programs.


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243